Condition: Neuroendocrine Carcinoma · Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Based on the efficacy of tarlatamab in patients with small-cell lung cancer, we aim to assess the efficacy of tarlatamab in patients with Advanced, pulmonary (large-cell only) or gastroenteropancreatic neuroendocrine carcinoma.
This description comes directly from the study's public registry record.
Contact IFCT · +33 1.56.81.10.45 · contact@ifct.fr
Always discuss trial participation with your own doctor first.
| Angers - CHU | Angers, France | Recruiting |
| Avignon - CH | Avignon, France | Recruiting |
| Besançon - CHU | Besançon, France | Recruiting |
| Boulogne - Ambroise Paré | Boulogne, France | Recruiting |
| Caen - CHU | Caen, France | Recruiting |
| Caen - CHU | Caen, France | Recruiting |
| Tours - CHU | Chambray-lès-Tours, France | Recruiting |
| Dijon - Centre Georges-François Leclerc | Dijon, France | Recruiting |
| Dijon - CHU Bocage | Dijon, France | Recruiting |
| Grenoble - CHU | Grenoble, France | Recruiting |
| Le Mans - CHG | Le Mans, France | Recruiting |
| Lille - Centre Oscar Lambret | Lille, France | Recruiting |
+ 28 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06937905